We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo's (MASI) ORi-Guided OLV Procedure Favored by New Study
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) recently announced the findings of a favorable study result after evaluating the utility and impact of Masimo Patient SafetyNet that was published in the Journal of PeriAnesthesia Nursing. The findings are based on the observation of nurses before and after the implementation of the Patient SafetyNet.
The study was aimed at assessing whether Oxygen Reserve Index (ORi) could prevent the adverse impacts of hyperoxemia (increase in arterial oxygen partial pressure) with a non-invasive probe during One-Lung Ventilation (“OLV”) procedures.
For investors’ note, ORi has been available outside the United States since 2014. It is a non-invasive and continuous parameter developed to offer additional insight into a patient's oxygen status under supplemental oxygen. However, ORi has not yet been cleared by the FDA and is not available in the United States.
The latest positive study outcome is a major stepping stone for Masimo’s patient monitoring business across the world.
Significance of the Study
The ORi monitoring is enabled by the Pulse CO-Oximetry platform (multi-wavelength rainbow), and is provided alongside oxygen saturation (SpO2) measured by the company’s SET pulse oximetry.
During OLV, which is a common technique for enabling a wide variety of pulmonary procedures, 100% fraction of inspired oxygen (FiO2) supplemental oxygen administration is generally used. This exposes patients to the possibility of hyperoxia-induced lung injury. Hence, researchers seek to determine whether ORi could prevent such an occurrence during OLV.
The study findings indicate that the adjustment of ORi with peripheral oxygen saturation and blood gas analysis demonstrates that hyperoxemia could be prevented during OLV in patients under anesthesia. Further, it was concluded that ORi-guided thoracic anesthesia may lead to reduced hospital stay and increased patient safety.
Industry Prospects
Per a report by Research and Markets, the global market for anesthesia and respiratory devices was estimated at $32.9 billion in 2020 and is projected to reach $47.7 billion by 2027 at a CAGR of 5.5%. Factors like the ongoing pandemic-led demand surge and rising incidence of respiratory diseases are likely to drive the market.
Given the market potential, the positive study outcome is likely to provide a significant boost to Masimo’s business globally.
Notable Developments
Of late, Masimo has witnessed a few notable developments across its business.
The company, in May, announced the findings of a study which found that the use of Patient SafetyNet with Masimo SET Pulse Oximetry and Acoustic Respiratory Rate monitoring significantly reduces nursing workload related to postoperative respiratory assessment. This result was also published in the Journal of PeriAnesthesia Nursing.
The same month, Masimo announced the publication of a study in the Journal of Anesthesia & Clinical Research in which researchers assessed the utility of Masimo O3 Regional Oximetry to aid in monitoring septic shock patients admitted to the ICU.
Again, in May, the company announced the publication of a study in the Journal of Applied Physiology in which researchers evaluated the utility of Masimo PVi as a non-invasive method of predicting preload responsiveness in patients treated with nasal high-flow therapy.
Price Performance
Shares of the company have lost 0.1% in the past year compared with the industry’s 17.6% growth and the S&P 500's 38.5% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Masimo carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) , AMN Healthcare Services Inc (AMN - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
AMN Healthcare’s long-term earnings growth rate is estimated at 6.5%. It currently carries a Zacks Rank #2.
National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
Image: Bigstock
Masimo's (MASI) ORi-Guided OLV Procedure Favored by New Study
Masimo Corporation (MASI - Free Report) recently announced the findings of a favorable study result after evaluating the utility and impact of Masimo Patient SafetyNet that was published in the Journal of PeriAnesthesia Nursing. The findings are based on the observation of nurses before and after the implementation of the Patient SafetyNet.
The study was aimed at assessing whether Oxygen Reserve Index (ORi) could prevent the adverse impacts of hyperoxemia (increase in arterial oxygen partial pressure) with a non-invasive probe during One-Lung Ventilation (“OLV”) procedures.
For investors’ note, ORi has been available outside the United States since 2014. It is a non-invasive and continuous parameter developed to offer additional insight into a patient's oxygen status under supplemental oxygen. However, ORi has not yet been cleared by the FDA and is not available in the United States.
The latest positive study outcome is a major stepping stone for Masimo’s patient monitoring business across the world.
Significance of the Study
The ORi monitoring is enabled by the Pulse CO-Oximetry platform (multi-wavelength rainbow), and is provided alongside oxygen saturation (SpO2) measured by the company’s SET pulse oximetry.
During OLV, which is a common technique for enabling a wide variety of pulmonary procedures, 100% fraction of inspired oxygen (FiO2) supplemental oxygen administration is generally used. This exposes patients to the possibility of hyperoxia-induced lung injury. Hence, researchers seek to determine whether ORi could prevent such an occurrence during OLV.
The study findings indicate that the adjustment of ORi with peripheral oxygen saturation and blood gas analysis demonstrates that hyperoxemia could be prevented during OLV in patients under anesthesia. Further, it was concluded that ORi-guided thoracic anesthesia may lead to reduced hospital stay and increased patient safety.
Industry Prospects
Per a report by Research and Markets, the global market for anesthesia and respiratory devices was estimated at $32.9 billion in 2020 and is projected to reach $47.7 billion by 2027 at a CAGR of 5.5%. Factors like the ongoing pandemic-led demand surge and rising incidence of respiratory diseases are likely to drive the market.
Given the market potential, the positive study outcome is likely to provide a significant boost to Masimo’s business globally.
Notable Developments
Of late, Masimo has witnessed a few notable developments across its business.
The company, in May, announced the findings of a study which found that the use of Patient SafetyNet with Masimo SET Pulse Oximetry and Acoustic Respiratory Rate monitoring significantly reduces nursing workload related to postoperative respiratory assessment. This result was also published in the Journal of PeriAnesthesia Nursing.
The same month, Masimo announced the publication of a study in the Journal of Anesthesia & Clinical Research in which researchers assessed the utility of Masimo O3 Regional Oximetry to aid in monitoring septic shock patients admitted to the ICU.
Again, in May, the company announced the publication of a study in the Journal of Applied Physiology in which researchers evaluated the utility of Masimo PVi as a non-invasive method of predicting preload responsiveness in patients treated with nasal high-flow therapy.
Price Performance
Shares of the company have lost 0.1% in the past year compared with the industry’s 17.6% growth and the S&P 500's 38.5% rise.
Zacks Rank & Key Picks
Currently, Masimo carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) , AMN Healthcare Services Inc (AMN - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
Veeva Systems’ long-term earnings growth rate is estimated at 15.8%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare’s long-term earnings growth rate is estimated at 6.5%. It currently carries a Zacks Rank #2.
National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>